Compare GDDY & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDDY | DVA |
|---|---|---|
| Founded | 1997 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 14.9B |
| IPO Year | 2014 | 2003 |
| Metric | GDDY | DVA |
|---|---|---|
| Price | $112.39 | $185.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 8 |
| Target Price | $106.75 | ★ $219.86 |
| AVG Volume (30 Days) | ★ 1.7M | 577.2K |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 3.43 | ★ 6.86 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $5.79 | $3.77 |
| Revenue Next Year | $5.24 | $3.39 |
| P/E Ratio | $33.36 | ★ $27.19 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $71.59 | $101.00 |
| 52 Week High | $137.93 | $247.49 |
| Indicator | GDDY | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 64.88 | 53.11 |
| Support Level | $81.16 | $173.98 |
| Resistance Level | N/A | $202.63 |
| Average True Range (ATR) | 3.23 | 5.66 |
| MACD | 1.12 | 0.65 |
| Stochastic Oscillator | 87.03 | 68.13 |
GoDaddy is a domain registrar, web hosting provider, and website-building platform. As a domain registrar, GoDaddy earns revenue via primary registrations, aftermarket purchases, and renewals. The firm also offers subscriptions spanning digital marketing and productivity tools, do-it-yourself and AI-powered website and online store building, and point-of-sale and payment facilitation solutions. Customers can also purchase add-ons, such as domain protection services against bad actors and other online risks, as well as web hosting.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.